S66 — Star Combo Pharma Income Statement
0.000.00%
- AU$15.53m
- AU$6.71m
- AU$26.28m
- 74
- 91
- 48
- 80
Annual income statement for Star Combo Pharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | AAS | AAS | AAS | AAS | AAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 39.1 | 27.1 | 23.9 | 25 | 26.3 |
Cost of Revenue | |||||
Gross Profit | 4.06 | 3.54 | 5.34 | 5.13 | 5.98 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 40.8 | 35.3 | 24.9 | 28.2 | 25.1 |
Operating Profit | -1.71 | -8.21 | -0.957 | -3.22 | 1.18 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.906 | -7.46 | -1.08 | -3.45 | 1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.349 | -7.88 | -0.696 | -4 | 0.747 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.349 | -7.88 | -0.696 | -4 | 0.747 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.349 | -7.88 | -0.696 | -4 | 0.747 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.001 | -0.028 | 0.002 | -0.008 | 0.006 |
Dividends per Share |